 | |
| Clinical data | |
|---|---|
| Pronunciation | /əˈlɛktɪnɪb/ ə-LEK-ti-nib |
| Trade names | Alecensa |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a616007 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth (capsules) |
| Drug class | Tyrosine kinase inhibitor[1] |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 37% (under fed conditions) |
| Protein binding | >99% |
| Metabolism | Mainly CYP3A4 |
| Metabolites | M4 (active) |
| Elimination half-life | 33 hours (alectinib), 31 hours (M4) |
| Excretion | Feces (98%)[2] |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C30H34N4O2 |
| Molar mass | 482.628 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Alectinib, sold under the brand name Alecensa, is a medication used to treat non-small-cell lung cancer (NSCLC).[3] It is used for advanced disease that is anaplastic lymphoma kinase (ALK) positive.[3] It is taken by mouth.[1]
Common side effects include tiredness, constipation, swelling, muscle pain, and low red blood cells.[4] Other side effects may include liver problems, pneumonitis, kidney problems, and muscle breakdown.[4] Use in pregnancy may harm the baby.[4] It is a tyrosine kinase inhibitor that blocks ALK.[1][3]
Alectinib was approved in Japan in 2014, the United States in 2015, and Europe in 2017.[4][3][5] In the United Kingdom 4 weeks costs the NHS about £5,000 as of 2021.[1] This amount in the United States is about 16,000 USD.[6]
References
edit- ^ a b c d e BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1012. ISBN 978-0857114105.
- ^ "Alecensa (alectinib) Capsules, for Oral Use. Full Prescribing Information" (PDF). Genentech USA, Inc. Archived (PDF) from the original on 11 February 2017. Retrieved 8 February 2017.
- ^ a b c d e "Alecensa". Archived from the original on 13 October 2021. Retrieved 13 January 2022.
- ^ a b c d e "DailyMed - ALECENSA- alectinib hydrochloride capsule". dailymed.nlm.nih.gov. Archived from the original on 9 November 2021. Retrieved 13 January 2022.
- ^ Takiguchi, Yuichi (24 January 2017). Molecular Targeted Therapy of Lung Cancer. Springer. p. 128. ISBN 978-981-10-2002-5. Archived from the original on 14 January 2022. Retrieved 13 January 2022.
- ^ "Alecensa Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 14 April 2021. Retrieved 13 January 2022.